Sugi Predict

Sugi Predict / Compounds / SCHEMBL17570951

SCHEMBL17570951

SCHEMBL17570951

COC(=O)CCCCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 5/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ SLC6A5 Q9Y345 1/20 0.44
▸ TSHR P16473 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ MME P08473 1/20 0.39
▸ ACE P12821 1/20 0.39
▸ CPA1 P15085 1/20 0.39
▸ ACE2 Q9BYF1 1/20 0.39
▸ REN P00797 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17570970 1.00 FAAH (0.50) FAAHSMN1; SMN2SLC6A5TSHRALDH1A1
SCHEMBL18924154 0.86 FAAH (0.43) FAAHSMN1; SMN2SLC6A5TSHRALDH1A1
SCHEMBL17570945 0.86 FAAH (0.43) FAAHSMN1; SMN2SLC6A5TSHRALDH1A1
SCHEMBL22019559 0.86 TSHR (0.42) FAAHTSHRALDH1A1LMNARECQL
SCHEMBL22019557 0.86 TSHR (0.42) FAAHTSHRALDH1A1LMNARECQL
SCHEMBL25052997 0.85 FAAH (0.54) FAAHSMN1; SMN2SLC6A5ALDH1A1LMNA
SCHEMBL21549707 0.84 FAAH (0.51) FAAHSMN1; SMN2SLC6A5TSHRALDH1A1
SCHEMBL21585637 0.83 FAAH (0.69) FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT
SCHEMBL10723213 0.83 FAAH (0.69) FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT
SCHEMBL21585636 0.83 FAAH (0.69) FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3380525-B1 PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF IMMUNOGEN INC (US) 2023-11-08 — — EP disclosed
US-11793885-B2 Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders IMMUNOGEN, INC. (US) 2023-10-24 — — US disclosed
US-20230286914-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-09-14 — — US disclosed
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents IMMUNOGEN, INC. (US) 2023-08-22 — — US disclosed
US-20230257400-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-08-17 — — US disclosed
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 — — US disclosed
EP-3778602-B1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN INC (US) 2023-07-12 — — EP disclosed
EP-4163284-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES ImmunoGen, Inc. (US) 2023-04-12 — — EP disclosed
US-11332535-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IMMUNOGEN, INC. (US) 2022-05-17 — — US disclosed
US-11278628-B2 Pharmaceutical formulations and methods of use thereof IMMUNOGEN, INC. (US) 2022-03-22 — — US disclosed
US-9669102-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2017-06-06 — — US disclosed
US-20170050985-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-02-23 — — US disclosed
US-20170051011-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-02-23 — — US disclosed
US-20170029514-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IMMUNOGEN, INC. 2017-02-02 — — US disclosed
WO-2017015496-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. (US) 2017-01-26 — — WO disclosed
WO-2017004026-A1 ANTI-CD 123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IMMUNOGEN, INC. (US) 2017-01-05 — — WO disclosed
US-20160095938-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN, INC. 2016-04-07 — — US disclosed
US-20160082114-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2016-03-24 — — US disclosed
WO-2016036801-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. (US) 2016-03-10 — — WO disclosed
WO-2016036794-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN, INC. (US) 2016-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11278628-B2 Pharmaceutical formulations and methods of use thereof GABRA5, GABRA6, GABRA3 FAAH 2229/4885SMN1; SMN2 2995/4885SLC6A5 427/4885
US-11732038-B2 Conjugates comprising cell-binding agents and cytotoxic agents PCNA, EPCAM, MKI67 FAAH 2846/4885SMN1; SMN2 1659/4885SLC6A5 2499/4885
US-20230286914-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA3, GABRA5, GABRA6 FAAH 2024/4885SMN1; SMN2 2230/4885SLC6A5 2116/4885
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885
US-20230257400-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA3, GABRA5, GABRB3 FAAH 1775/4885SMN1; SMN2 1938/4885SLC6A5 1782/4885
US-20160082114-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885
US-20170050985-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA3, GABRA5, GABRB3 FAAH 1775/4885SMN1; SMN2 1938/4885SLC6A5 1782/4885
US-20170051011-A1 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA3, GABRA5, GABRB3 FAAH 1775/4885SMN1; SMN2 1938/4885SLC6A5 1782/4885
US-20170029514-A1 ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF IL23R, CD22, IL2RA FAAH 4226/4885SMN1; SMN2 4446/4885SLC6A5 4528/4885
US-20160095938-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS PCNA, EPCAM, MKI67 FAAH 2846/4885SMN1; SMN2 1659/4885SLC6A5 2499/4885
US-11332535-B2 Anti-CD123 antibodies and conjugates and derivatives thereof IL23R, CD22, IL2RA FAAH 4226/4885SMN1; SMN2 4446/4885SLC6A5 4528/4885
US-11793885-B2 Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders MKI67, GABBR1, GABBR2 FAAH 1832/4885SMN1; SMN2 3393/4885SLC6A5 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.